美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

VanEck Biotech ETF

232.02

+2.631.15%

盤後：231.90-0.1227-0.05%19:30 EDT

成交量：4,581

成交額：105.91萬

市值：4.66億

市盈率：- -

高：232.10

開：230.06

低：229.59

收：229.39

52周最高：244.35

52周最低：160.91

股本：200.65萬

流通股本：200.65萬

量比：0.48

換手率：0.23%

股息：0.96

股息率：0.42%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Revolution Medicines宣佈Rasonque™（Daraxonrasib）聯合化療獲美國FDA突破性療法認定，用於一線轉移性胰腺癌治療

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

Revolution Medicines獲摩根士丹利首次覆蓋，給予「增持」評級，目標價255美元

118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BBH"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","market":"US","secType":"STK","nameCN":"VanEck Biotech ETF","latestPrice":232.024,"timestamp":1789416000000,"preClose":229.3922,"halted":0,"volume":4581,"hourTrading":{"tag":"盘后","latestPrice":231.9013,"preClose":232.024,"latestTime":"19:30 EDT","volume":18,"amount":4175.136,"timestamp":1789428602348,"change":-0.1227,"changeRate":-0.000529,"amplitude":0},"delay":0,"changeRate":0.011472927152710503,"floatShares":2006503,"shares":2006503,"eps":0,"marketStatus":"未開盤","change":2.6318,"latestTime":"09-14 16:00:00 EDT","open":230.06,"high":232.1,"low":229.5938,"amount":1059133.20111,"amplitude":0.010925,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":229.3922,"sharesOutstanding":1976503,"nav":229.3061,"aum":460103384.52,"dividendRate":0.004152,"bidAskSpread":0.001038,"postHourTrading":{"tag":"盘后","latestPrice":231.9013,"preClose":232.024,"latestTime":"19:30 EDT","volume":18,"amount":4175.136,"timestamp":1789428602348,"change":-0.1227,"changeRate":-0.000529,"amplitude":0},"volumeRatio":0.482698,"impliedVol":0.187,"impliedVolPercentile":0.3745},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","floatShares":2006503,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.482698,"shares":2006503,"dividePrice":0.9634,"high":232.1,"amplitude":0.010925,"preClose":229.3922,"low":229.5938,"week52Low":160.91,"pbRate":"--","week52High":244.345,"institutionHeld":0,"latestPrice":232.024,"eps":0,"divideRate":0.004152,"volume":4581,"delay":0,"ttmEps":0,"open":230.06,"prevYearClose":189.2649,"prevWeekClose":229.3922,"prevMonthClose":236.396,"prevQuarterClose":203.2373,"fiveDayClose":241.1222,"twentyDayClose":218.0411,"sixtyDayClose":188.0998},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBH","amount":0.9565,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-12-23","symbol":"BBH","amount":1.2517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"BBH","amount":0.7127,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Biotech ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"BBH","amount":0.7488,"defaultRemindTime":1671460200000,"name":"VanEck Biotech ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"BBH","amount":0.3972,"defaultRemindTime":1640010600000,"name":"VanEck Vectors Biotech ETF","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.327,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.006,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4724,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.6079,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-27","value":0.3972,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBH\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1165924054","title":"Revolution Medicines宣佈Rasonque™（Daraxonrasib）聯合化療獲美國FDA突破性療法認定，用於一線轉移性胰腺癌治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1165924054","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165924054?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 04:06","pubTimestamp":1789416374,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc.今日宣布，其研发的创新药物Rasonque与化疗药物联用，已获得美国食品药品监督管理局授予的突破性疗法认定。这一认定针对的适应症为一线治疗转移性胰腺癌。此项突破性疗法认定标志着该联合治疗方案在临床试验中展现出显著的治疗潜力，有望为预后极差的转移性胰腺癌患者带来新的治疗选择。这一进展不仅为Revolution Medicines的研发管线注入了强劲动力，也让医学界对攻克胰腺癌这一顽固性疾病增添了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE0009355771.USD","PTH","IE0009354923.USD","CANC","IE00B4R5TH58.HKD","BK4139","IE0002141913.USD","IDNA","IE00B2B36J28.USD","BBH","IE00BJJMRZ35.SGD","RVMD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PBPH","LU2322448791.USD","IEHS","HELX","GNOM","LU1992135399.USD","TMED","BIB","FBT","XPH","PPH","BK4588","LU2272731865.HKD","RXL","PBE","LU1992135472.HKD","CANC","SYNB","MEDI","BME","BBP","BBH","XBIX","RSPH","IE00B5TLWC47.USD","IDNA","IBB","BIOY","PJP","IBRN","MRNX","LU2272731600.USD","IEIH","FTXH","AZNH","IYH","LFSC","LU2322448957.HKD","BK4585","PSCH","SBIO","MRNY","WDNA","LU2473716301.USD","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186962882","title":"Revolution Medicines獲摩根士丹利首次覆蓋，給予「增持」評級，目標價255美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186962882","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186962882?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 18:10","pubTimestamp":1789035009,"startTime":"0","endTime":"0","summary":"摩根士丹利近日宣布首次覆盖生物制药公司Revolution Medicines, Inc.，并给予其“增持”评级。该机构将目标股价设定为每股255美元。这一举措标志着华尔街主要投行对这家专注于研发创新疗法的企业前景持乐观态度。值得注意的是，摩根士丹利的这一评级和价格目标，为投资者提供了新的参考坐标。此前，市场对Revolution Medicines的关注度持续攀升，尤其在肿瘤治疗领域，其管线布局备受瞩目。此次覆盖报告的出炉，或将在短期内影响该股的市场情绪与交易动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","BK4139","IE00BJT1NW94.SGD","IE0002141913.USD","LU0109394709.USD","LU0320765992.SGD","RVMD","IE00BFTCPJ56.SGD","IDNA","IE0009355771.USD","PTH","IE00B2B36J28.USD","CANC","IE00BJJMRZ35.SGD","IE0009354923.USD","LU0889565916.HKD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666563124","title":"118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563124","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666563124?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:26","pubTimestamp":1789025185,"startTime":"0","endTime":"0","summary":"BCG合伙人杜菁博士指出，未来几年全球MNC将迎来史上最大专利悬崖，有118种生物制剂将会失去相应的专利保护，涉及2340亿美元市场。然而，目前这118款即将到期分子中，只有极少数在火热开发，大量缺口有待生物类似药填补。目前来说，创新药出海还没办法完成这个闭环，但生物类似药作为先头部队做出海试验，企业风险和获益会更高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789025064363150858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["RSPH","159839","PJP","BBP","APXH","BME","MEDI","TMED","PBPH","GSKH","IHE","BBH","IYH","PPH","TRUH","FXH","JDOC","FHLC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":47,"pageCount":1,"totalSize":187,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BBH\",params:#limit:6,delay:false,,,undefined,":[]}}